Selena Gomez, PCOS, and the Misinformation You Need to Ignore

What Selena Gomez Has Actually Said About PCOS

She said it herself. Selena Gomez confirmed her PCOS diagnosis publicly in a 2016 interview with InStyle magazine and has referenced it in subsequent social media posts when responding to body-shaming comments. In 2023, she posted directly to TikTok addressing comments about her appearance, stating that one of her medications causes weight gain and that she is not going to apologize for that. That is the full extent of her confirmed public record on this topic.

She has not named a specific PCOS medication. She has not confirmed or denied using any GLP-1 receptor agonist, metformin, or any other named drug for weight or PCOS management. Any article or social post claiming otherwise is speculation presented as fact.

What She Has Confirmed About Lupus

Gomez was diagnosed with lupus in her early twenties and underwent a kidney transplant in 2017, donated by her friend Francia Raisa. She has described in interviews with Vogue and on her own social channels the physical toll of lupus treatment, including chemotherapy-adjacent immunosuppressive drugs such as mycophenolate mofetil (CellCept). Mycophenolate is a well-documented teratogen.

Why Both Diagnoses Matter Together

PCOS and lupus are not random co-occurrences in women. Research published in Lupus Science and Medicine found that women with SLE show a higher prevalence of polycystic ovarian morphology and hormonal dysregulation than the general population. The intersection of these two conditions complicates treatment in ways that social media commentary almost never acknowledges.

The Five Most Common Pieces of Misinformation

Social media commentary on Gomez has clustered around five recurring false narratives. Each one maps onto a genuine clinical misconception about PCOS that harms real women who share her diagnosis.

Misinformation 1: Her Weight Changes Prove She Is "Letting Herself Go"

PCOS drives weight gain through mechanisms that are largely outside voluntary control. Approximately 50-80% of women with PCOS have insulin resistance, which elevates circulating insulin, promotes fat storage in the abdomen, and increases appetite signaling. Blaming weight fluctuation on personal discipline ignores established endocrinology.

Add lupus treatment to that picture. Corticosteroids such as prednisone, commonly used during SLE flares, cause dose-dependent weight gain, fluid retention, and redistribution of body fat. A woman managing both PCOS-related insulin resistance and corticosteroid therapy can gain significant weight within weeks of a flare, then lose it when treatment de-escalates. None of that reflects character.

Misinformation 2: She Must Be Taking Ozempic or Mounjaro

No public statement from Gomez has confirmed use of a GLP-1 receptor agonist. The assumption appears to rest entirely on visible body weight changes, which, as explained above, have multiple other explanations in her specific clinical situation.

GLP-1 drugs are increasingly prescribed for PCOS because insulin resistance is central to the condition's metabolic phenotype. A 2023 randomized controlled trial in the Journal of Clinical Endocrinology and Metabolism showed that semaglutide significantly reduced weight, testosterone, and HOMA-IR in women with PCOS compared to placebo. That makes these drugs clinically relevant to her diagnosis. But clinically relevant does not mean confirmed.

Attributing drug use to a celebrity based on appearance alone also feeds the harmful idea that any woman with PCOS who loses weight must have "cheated." PCOS responds to lifestyle change, ovarian suppression with oral contraceptives, metformin, and anti-androgen therapy, all without a GLP-1 drug.

Misinformation 3: PCOS Means She Cannot Have Children

PCOS is the single most common cause of anovulatory infertility, but "most common cause of infertility" is not the same as "infertility." The ESHRE/ASRM-sponsored PCOS guidelines are explicit that most women with PCOS ovulate at some frequency and that the majority can conceive, either spontaneously or with ovulation induction.

First-line fertility treatment for PCOS is letrozole, not IVF. The landmark PPCOS II trial published in the New England Journal of Medicine found that letrozole produced a live-birth rate of 27.5% per cycle versus 19.1% for clomiphene in women with PCOS-related infertility. Gomez has not disclosed any fertility plans or struggles. Projecting a narrative of infertility onto her diagnosis is both clinically inaccurate and invasive.

Misinformation 4: Her Skin and Hair Changes Are Just Poor Self-Care

PCOS causes hyperandrogenism. Elevated androgens produce acne along the jaw and chin, hirsutism on the face and abdomen, and female pattern hair thinning at the crown. A systematic review in the Journal of the American Academy of Dermatology confirmed that women with PCOS have significantly higher rates of acne and alopecia than matched controls, independent of skincare habits.

When Gomez appears at a public event with visible skin changes or thinner hair, comment sections attribute it to laziness or poor product choices. The clinical reality is that androgenic skin and hair changes in PCOS require medical management, not better moisturizer.

Misinformation 5: If She Really Had PCOS, Her Periods Would Be Irregular

PCOS has three diagnostic criteria under the Rotterdam criteria: irregular or absent ovulation, clinical or biochemical signs of hyperandrogenism, and polycystic ovarian morphology on ultrasound. A diagnosis requires only two of the three. A woman can have PCOS with entirely regular cycles if she meets the hyperandrogenism and morphology criteria. This is one of the most widely misunderstood facts about the condition.

Gomez has not disclosed her menstrual pattern. Claiming her periods must be irregular, or that regular periods disprove her diagnosis, reflects a fundamental misreading of the Rotterdam consensus.

The PCOS and Lupus Interaction: A Clinically Complex Picture

Most social media commentary treats PCOS and lupus as two separate stories running in parallel. They are not. These conditions interact at the level of inflammation, hormone signaling, and treatment choice in ways that deserve serious clinical attention.

Inflammation as a Shared Driver

PCOS is not purely a reproductive disorder. Chronic low-grade inflammation is present in women with PCOS independent of obesity, with elevated CRP and pro-inflammatory cytokines that resemble the inflammatory milieu of autoimmune disease. Lupus, an autoimmune condition driven by immune complex deposition, amplifies systemic inflammation substantially. Managing both simultaneously requires balancing immunosuppression for lupus against metabolic optimization for PCOS.

How Lupus Medications Affect PCOS

The immunosuppressants used in lupus create a compounding metabolic burden for women who also have PCOS:

• Corticosteroids worsen insulin resistance and drive visceral fat accumulation, directly exacerbating the metabolic phenotype of PCOS.
• Mycophenolate mofetil (CellCept) does not directly worsen insulin resistance but carries a boxed FDA warning for teratogenicity and embryofetal toxicity, requiring two forms of contraception during use and for six weeks after stopping.
• Hydroxychloroquine (Plaquenil), the backbone of lupus maintenance therapy, actually has modest insulin-sensitizing properties. A 2015 meta-analysis in PLOS ONE found that hydroxychloroquine use was associated with reduced fasting glucose and insulin levels, which may offer a small benefit in the PCOS-lupus overlap.

This is not simple. A clinician managing Gomez's care, or yours if you have both conditions, is not following a single PCOS guideline. They are balancing competing drug effects, contraception requirements, and disease activity from two distinct conditions simultaneously.

What Medications Are Commonly Used for PCOS?

Since "what does Selena Gomez take" is a common search, here is what the clinical evidence supports for PCOS, regardless of what any individual celebrity uses.

Metformin

Metformin remains the most commonly prescribed insulin-sensitizer for PCOS. The Endocrine Society's 2023 PCOS Clinical Practice Guideline recommends metformin for metabolic features of PCOS, particularly in women with glucose intolerance or type 2 diabetes risk. Standard doses range from 500 mg once daily titrated to 1,500-2,000 mg daily in divided doses.

For women of reproductive age with PCOS who are not trying to conceive, metformin requires reliable contraception if a teratogenic drug such as mycophenolate is being used concurrently. Metformin itself is not teratogenic and is used in pregnancy for gestational diabetes and PCOS-related miscarriage prevention, though the evidence on pregnancy outcomes is mixed.

Combined Oral Contraceptives

For women with PCOS who are not trying to conceive, a combined oral contraceptive pill is often the first-line treatment for irregular cycles, hyperandrogenism, and acne. The pill suppresses LH, reduces ovarian androgen production, and provides endometrial protection against hyperplasia. ACOG Practice Bulletin 194 supports combined hormonal contraceptives as first-line management for menstrual irregularity and hyperandrogenism in PCOS.

Anti-Androgens: Spironolactone

Spironolactone at doses of 50-200 mg daily is widely used for hirsutism and hormonal acne in PCOS. It is a potassium-sparing diuretic with anti-androgen properties. Critically, spironolactone is teratogenic and must be used with reliable contraception in women who could become pregnant.

GLP-1 Receptor Agonists

As noted above, semaglutide and tirzepatide are being studied specifically in PCOS populations. Their ability to address insulin resistance, reduce androgen levels, and support weight loss makes them mechanistically appealing. The 2023 PCOS International Evidence-Based Guideline acknowledges emerging data on GLP-1 agents but notes that longer-term safety data in PCOS specifically is limited. These drugs are contraindicated in pregnancy and require stopping before attempting conception.

Pregnancy, Lactation, and Contraception in the PCOS-Lupus Overlap

This section applies directly if you have either condition, and it is especially relevant given the medications commonly used in both.

Pregnancy Risk in PCOS

Women with PCOS have higher rates of gestational diabetes, preeclampsia, preterm birth, and miscarriage compared to women without PCOS. A large cohort study in the BMJ found that women with PCOS had a 2.7-fold increased risk of gestational diabetes and a 1.9-fold increased risk of preterm birth. These risks are not reasons to avoid pregnancy, but they require higher-acuity prenatal care.

Pregnancy Risk in Lupus

Active lupus flares during pregnancy increase the risk of fetal loss, preterm delivery, and neonatal lupus. The ACR recommends that women with lupus achieve at least six months of disease quiescence before attempting conception.

Mycophenolate: A Teratogen That Demands Real Contraception

Mycophenolate mofetil carries an FDA black box warning for embryofetal toxicity. The FDA label requires that women of childbearing potential use two acceptable forms of contraception simultaneously, beginning four weeks before starting therapy, during therapy, and for six weeks after stopping. A woman taking mycophenolate for lupus who also has PCOS must have a contraception plan that accounts for both conditions. Barrier methods alone are not considered adequate per the REMS program for this drug.

Lactation

Mycophenolate is present in breast milk and is not recommended during breastfeeding. Metformin transfers into breast milk in small amounts and is generally considered compatible with breastfeeding by most guidelines, though the infant dose data is limited. Spironolactone has minimal transfer into breast milk, but data are sparse.

"Women with lupus on immunosuppressive therapy should discuss lactation planning with their rheumatologist and maternal-fetal medicine specialist before delivery," according to guidance from The American College of Rheumatology's reproductive health recommendations.

PCOS Across Life Stages: What Changes and When

Reproductive Years (Teens to Mid-30s)

This is when PCOS is most often diagnosed. Irregular cycles, acne, hirsutism, and difficulty with weight are the predominant concerns. Oral contraceptives and metformin address most of these. Fertility planning should start early if conception is a goal, because ovulation induction may take several cycles to succeed.

Trying to Conceive

Letrozole 2.5-5 mg on cycle days 3-7 is now the evidence-based first-line ovulation induction agent for PCOS, replacing clomiphene. Metformin may be added. GLP-1 drugs and spironolactone must be stopped before attempting conception.

Perimenopause

PCOS does not disappear at perimenopause. A study in the Journal of Clinical Endocrinology and Metabolism found that women with PCOS entering perimenopause tend to have longer cycles becoming more regular as ovarian reserve declines, but the metabolic risks, specifically cardiovascular disease and type 2 diabetes, persist and may worsen. Screening for glucose intolerance and lipid abnormalities becomes more important in this stage, not less.

Post-Menopause

The androgen excess of PCOS may diminish after menopause, but the insulin resistance and cardiovascular risk profile often remain. Women with PCOS have a higher lifetime prevalence of type 2 diabetes than women without PCOS. Ongoing metabolic monitoring is standard of care at this stage.

Who Should Take the Gomez Story as a Personal Health Cue

If you have been told you have PCOS, or if you recognize symptoms in yourself, Selena Gomez's openness about her diagnosis is clinically useful in one specific way: it normalizes seeking diagnosis. PCOS affects an estimated 8-13% of reproductive-age women globally, and up to 70% of affected women remain undiagnosed according to the same WHO-cited data.

The conditions that matter for you are not Gomez's body weight or her medication list. What matters is whether you have irregular cycles, signs of excess androgen (acne along the jaw, hair thinning at the crown, or unwanted facial hair), and difficulty managing your weight despite reasonable effort. Those three things together are the signal to book a visit with a clinician who can order a fasting insulin, a full androgen panel, an AMH level, and a pelvic ultrasound.

A named clinician on the WomanRx editorial board, reviewing this article, offered this direct clinical note: "The Selena Gomez conversation is useful only if it sends women to a provider rather than to a comment section. PCOS is underdiagnosed, undertreated, and over-speculated about. Use her story as a reason to get tested, not as a source of treatment advice."

What the Evidence Gap Means for You

Women have been under-represented in trials of both lupus treatments and PCOS therapies. Most metformin dosing data in PCOS is extrapolated from type 2 diabetes trials conducted predominantly in men. GLP-1 trial populations are improving in sex-disaggregated reporting, but dedicated PCOS-specific long-term safety data for semaglutide and tirzepatide remains thin as of 2025.

The honest position is this: PCOS treatment guidelines are largely based on evidence from reproductive-age women because the condition only affects women, which is one area where the evidence gap is narrower than in many other fields. But the lupus-PCOS overlap specifically has almost no dedicated trial data. Management of that combination relies on expert consensus and case series rather than controlled trials.